Epidermal growth factor receptor L858R mutated allosteric inhibitor (Allorion Therapeutics/AstraZeneca)

N/A

Report date: 2026/05/08 20:02:52
NME

Base Information

Drug NameEpidermal growth factor receptor L858R mutated allosteric inhibitor (Allorion Therapeutics/AstraZeneca)
Drug Alias NameEGFR L858R allosteric inhibitor (Allorion Therapeutics/AstraZeneca)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionEGFR L858R inhibitors
TargetsEGFR L858R
Therapy Area/IndicationsCarcinoma, Non-Small-Cell Lung
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesAllorion Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesAllorion Therapeutics IncAstrazeneca Plc
Inactive CompaniesN/A
Active IndicationsCarcinoma, Non-Small-Cell Lung
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A